Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular
- PMID: 37714257
- DOI: 10.1016/j.canlet.2023.216391
Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly life-threatening tumour with a low early-detection rate, rapid progression and a tendency to develop resistance to chemotherapy. Therefore, understanding the regulatory mechanisms underlying the initiation, development and metastasis of pancreatic cancer is necessary for enhancing therapeutic effectiveness. In this review, we summarised single-gene mutations (including KRAS, CDKN2A, TP53, SMAD4 and some other less prevalent mutations), epigenetic changes (including DNA methylation, histone modifications and RNA interference) and large chromosome alterations (such as copy number variations, chromosome rearrangements and chromothripsis) associated with PDAC. In addition, we discussed variations in signalling pathways that act as intermediate oncogenic factors in PDAC, including PI3K/AKT, MAPK/ERK, Hippo and TGF-β signalling pathways. The focus of this review was to investigate alterations in the microenvironment of PDAC, particularly the role of immunosuppressive cells, cancer-associated fibroblasts, lymphocytes, other para-cancerous cells and tumour extracellular matrix in tumour progression. Peripheral axons innervating the pancreas have been reported to play a crucial role in the development of cancer. In addition, tumour cells can influence the behaviour of neighbouring non-tumour cells by secreting certain factors, both locally and at a distance. In this review, we elucidated the alterations in intracellular molecules and the extracellular environment that occur during the progression of PDAC. Altogether, this review may enhance the understanding of the biological characteristics of PDAC and guide the development of more precise treatment strategies.
Keywords: Molecular alterations; PDAC; Signalling pathway; Tumour microenvironment.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.Carcinogenesis. 2020 Mar 13;41(1):44-55. doi: 10.1093/carcin/bgz086. Carcinogenesis. 2020. PMID: 31046123
-
Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.Br J Surg. 2016 Aug;103(9):1189-99. doi: 10.1002/bjs.10187. Epub 2016 Jun 3. Br J Surg. 2016. PMID: 27256393
-
Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).Front Immunol. 2022 Dec 14;13:1060957. doi: 10.3389/fimmu.2022.1060957. eCollection 2022. Front Immunol. 2022. PMID: 36591282 Free PMC article.
-
Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma - Heading towards a promising change in treatment paradigm.Cancer Treat Rev. 2024 Jun;127:102750. doi: 10.1016/j.ctrv.2024.102750. Epub 2024 May 3. Cancer Treat Rev. 2024. PMID: 38703592 Review.
-
Role of epigenetics in pancreatic ductal adenocarcinoma.Epigenomics. 2023 Jan;15(2):89-110. doi: 10.2217/epi-2022-0177. Epub 2023 Jan 17. Epigenomics. 2023. PMID: 36647796 Review.
Cited by
-
Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma.Cancer Lett. 2024 Aug 28;598:217097. doi: 10.1016/j.canlet.2024.217097. Epub 2024 Jul 2. Cancer Lett. 2024. PMID: 38964729 Free PMC article.
-
Pancreatic Cancer: Pathogenesis and Clinical Studies.MedComm (2020). 2025 Apr 2;6(4):e70162. doi: 10.1002/mco2.70162. eCollection 2025 Apr. MedComm (2020). 2025. PMID: 40182139 Free PMC article. Review.
-
Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer.Chin J Cancer Res. 2025 Jun 30;37(3):466-486. doi: 10.21147/j.issn.1000-9604.2025.03.13. Chin J Cancer Res. 2025. PMID: 40642496 Free PMC article.
-
Honey Targets Ribosome Biogenesis Components to Suppress the Growth of Human Pancreatic Cancer Cells.Cancers (Basel). 2024 Oct 9;16(19):3431. doi: 10.3390/cancers16193431. Cancers (Basel). 2024. PMID: 39410048 Free PMC article.
-
Single-Cell Analysis Differentiates the Effects of p53 Mutation and p53 Loss on Cell Compositions of Oncogenic Kras-Driven Pancreatic Cancer.Cells. 2023 Nov 12;12(22):2614. doi: 10.3390/cells12222614. Cells. 2023. PMID: 37998349 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous